Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ICUBullishCorporate Developmentsnews

High materiality8/10

CMS ICD-10-PCS Codes for QUELIMMUNE Could Accelerate ICU AKI Adoption

Jun 23, 2026, 8:28 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory coding codes and a large TAM for adult AKI create tangible near-term upside potential; adoption hinges on trial outcomes but the reimbursement framework materially lowers deployment barriers in ICUs.

AI summary

What happened, with direct paths to the underlying reporting

SeaStar Medical announced dedicated ICD-10-PCS codes for QUELIMMUNE SCD-PED, enabling inpatient billing for AKI requiring RRT. Codes take effect October 1, 2026 and could unlock rapid adoption in a $4.5B adult AKI market, about 50x the pediatric market. The NEUTRALIZE-AKI trial in 339 adults will be a key readout for potential expansion into ICU AKI indications.

CMS assigns ICD-10-PCS codes for QUELIMMUNE. Codes take effect Oct 1, 2026.
Adult AKI market potential around $4.5B; ~50x pediatric.
NEUTRALIZE-AKI trial: 339 adults; primary endpoint 90-day mortality or dialysis.
QUELIMMUNE (SCD-PED) approved Feb 2024; pediatric ICU use.
Codes to ease hospital billing and broaden adoption.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.